Korea S.E.
23:00:00 01/07/2024 BST
5-day change
1st Jan Change
3,460
KRW
+7.79%
+9.49%
+15.33%
Vivozon Healthcare, Inc. announced that it has received KRW 58.171164251 billion in funding from Vaultea, Inc. and other investors
On April 5, 2022, Vivozon Healthcare, Inc. closed the transaction.
Tranche Update on Vivozon Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on September 19, 2023.
21/09/23
CI
Vivozon Pharmaceutical Co., Ltd.'s Equity Buyback announced on September 19, 2023, has closed with 5,000,000 shares.
19/09/23
CI
Vivozon Pharmaceutical Co., Ltd. announces an Equity Buyback for 5,000,000 shares.
19/09/23
CI
Vivozon Pharmaceutical Co., Ltd. authorizes a Buyback Plan.
18/09/23
CI
Vivozon Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
15/05/23
CI
Vivozon Pharmaceutical Co., Ltd. announced that it has received KRW 2.000000072 billion in funding
27/02/23
CI
Vivozon Pharmaceutical Co., Ltd. announced that it expects to receive KRW 2.000000072 billion in funding
08/01/23
CI
Vivozon Pharmaceutical Co., Ltd. announced that it has received KRW 6 billion in funding
19/12/22
CI
Vivozon Healthcare, Inc. announced that it expects to receive KRW 6 billion in funding
10/11/22
CI
Vivozon Healthcare, Inc.(KOSDAQ:A082800) dropped from S&P Global BMI Index
26/08/22
CI
Vivozon Healthcare, Inc. announced that it has received KRW 58.171164251 billion in funding from Vaultea, Inc. and other investors
04/04/22
CI
Vivozon Healthcare, Inc. announced that it expects to receive KRW 58.171164251 billion in funding from Vaultea, Inc. and other investors
24/03/22
CI
Vivozon Healthcare, Inc. announced that it has received KRW 10 billion in funding from Korea Fixed Income Investment Advisory Co., Ltd.
16/12/21
CI
Vivozon Healthcare, Inc. announced that it expects to receive KRW 10 billion in funding from Korea Fixed Income Investment Advisory Co., Ltd.
09/05/21
CI
Osung Advanced Materials Co., Ltd. cancelled the acquisition of Rumi Technology & Loan CO.,LTD. from Lumimicro Co., Ltd for KRW 33.7 billion.
16/01/21
CI
December Fund 3, Nikkei Fund 3 and Pureun Fund 1 cancelled the acquisition of 23.85% stake in Lumimicro Co., Ltd from Osung Advanced Materials Co., Ltd. and S-MAC CO., Ltd..
17/11/20
CI
Vivozon Healthcare, Inc. announced that it has received KRW 30 billion in funding from Korea Fixed-Income Investment Advisory, Korea Bond Investment Advisory Co., Ltd.
04/11/20
CI
Lumimicro Co., Ltd completed the acquisition of 85.78% stake in Inist Bio Co.,Ltd. from Inistpharm Co.,Ltd, Kim, Kook-Hyun, Park, Ji-seop, Industrial Bank of Korea and others.
29/09/20
CI
Lumimicro Co., Ltd agreed to acquire 85.78% stake in Inist Bio Co.,Ltd. from Inistpharm Co.,Ltd, Kim, Kook-Hyun, Park, Ji-seop, Industrial Bank of Korea and others for KRW 60.9 billion.
22/09/20
CI
Vivozon Healthcare, Inc.(KOSDAQ:A082800) added to S&P Global BMI Index
21/09/20
CI
Vivozon Inc. announced that it has received KRW 49.9999865 billion in funding from Vivozon Healthcare, Inc.
30/06/20
CI
Vivozon Inc. announced that it expects to receive KRW 49.9999865 billion in funding from Lumimicro Co., Ltd
15/06/20
CI
S-MAC CO., Ltd. completed the acquisition of additional 8.22% stake in Kumho HT, Inc. from Lumimicro Co., Ltd.
11/06/20
CI
Lumimicro Co., Ltd announced that it expects to receive KRW 30 billion in funding from Korea Fixed-Income Investment Advisory, Korea Bond Investment Advisory Co., Ltd.
05/05/20
CI
Lumimicro Co., Ltd announced that it has received KRW 20 billion in funding
30/01/20
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Vivozon Pharmaceutical Co Ltd , formerly Vivozon Healthcare Inc, is a Korea-based company mainly engaged in the manufacture and sale of finished pharmaceutical products. The Company operates its business through three segments. The Pharmaceutical Business segment is engaged in the manufacture and sale of finished medicines such as external skin preparations, antipyretic analgesic, anti-inflammatory drugs and antidiabetic drugs. The Optical Business segment is engaged in the manufacture and sale of finished products and lighting module sets such as general lighting and automotive lighting using light emitting diode (LED) light sources. The Cosmetics Business segment is engaged in the manufacture and sale of cosmetics and cosmetic ingredients.
More about the company
1st Jan change
Capi.
+15.33% 110M +55.55% 823B +42.31% 641B -6.83% 352B +17.15% 324B +7.09% 301B +14.02% 241B +1.64% 223B +13.66% 218B +7.87% 167B
Other Pharmaceuticals
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
VIVOZON PHARMACEUTICAL CO., LTD. 
